A Website Directory of Healthcare Companies - Find, Research or Submit Healthcare Websites

Bio-Bridge Science is a biotech company focused on the commercial development of biological products for the prevention and treatment of human infectious diseases and production material in producing vaccines. We intend to develop and obtain regulatory approval for commercial sale of the following vaccines: an HIV vaccine (HIV-PV Vaccine I), a vaccine designed to prevent and treat infection by the human immunodeficiency virus, or HIV, an HPV vaccine, a colon cancer therapeutic vaccine and other related potential products. Also, we sell bovine serum, a major production material in producing vaccines, through our 51% owned subsidiary, XHBD. The HIV vaccine and colon cancer vaccine are based on the technology platform co-developed by Dr. Liang Qiao, our chief executive officer and an associate professor at Loyola University Chicago. The technology is owned by Loyola University. In June 2002, Loyola University exclusively licensed this technology to our subsidiary Bio-Bridge Science Corporation with respect to development and sales in the territories of People’s Republic of China, Japan and the United States.